Dual specificity tyrosine-phosphorylation-regulated kinase 1A · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Dual specificity tyrosine-phosphorylation-regulated kinase 1A shows late clinical disease relevance led by osteoarthritis, knee. 2 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q13627. Start with osteoarthritis, knee, then reuse UniProt Q13627 as the stable protein anchor across project notes and exports.
Start with osteoarthritis, knee, then reuse UniProt Q13627 as the stable protein anchor across project notes and exports.
Dual specificity tyrosine-phosphorylation-regulated kinase 1A shows late clinical disease relevance led by osteoarthritis, knee. 2 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with osteoarthritis, knee because it currently carries late clinical support. Linked drugs include LORECIVIVINT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyDual specificity tyrosine-phosphorylation-regulated kinase 1A
Review this target as Dual specificity tyrosine-phosphorylation-regulated kinase 1A, mapped to UniProt Q13627. Sequence length is 763 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Dual specificity tyrosine-phosphorylation-regulated kinase 1A as ChEMBL target CHEMBL2292, mapped to UniProt Q13627. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Dual specificity tyrosine-phosphorylation-regulated kinase 1A is the right protein anchor across sources, using UniProt Q13627 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why osteoarthritis, knee is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Dual specificity tyrosine-phosphorylation-regulated kinase 1A |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | Q13627 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Dual specificity tyrosine-phosphorylation-regulated kinase 1A |
| UniProt Accession | Q13627 |
| Component Type | Protein |
| Sequence Length | 763 aa |
Dual specificity tyrosine-phosphorylation-regulated kinase 1A
Review this target as Dual specificity tyrosine-phosphorylation-regulated kinase 1A, mapped to UniProt Q13627. Sequence length is 763 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Dual specificity tyrosine-phosphorylation-regulated kinase 1A shows late clinical disease relevance led by osteoarthritis, knee. 2 more disease programs remain visible in the same review block.
Start review with osteoarthritis, knee because it currently carries late clinical support. Linked drugs include LORECIVIVINT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL4647659 | 10.17 | Kd | 0.067 | Preclinical |
| CHEMBL4644916 | 10.12 | Kd | 0.075 | Preclinical |
| CHEMBL5070553 | 10.07 | Kd | 0.086 | Preclinical |
| CHEMBL393525 | 10.05 | Kd | 0.09 | Preclinical |
| CHEMBL5285332 | 10.0 | Kd | 0.101 | Preclinical |
| CHEMBL3688339 | 9.92 | Kd | 0.12 | Preclinical |
| CHEMBL4647416 | 9.8 | Kd | 0.16 | Preclinical |
| CHEMBL2386770 | 9.8 | IC50 | 0.16 | Preclinical |
| CHEMBL2386744 | 9.8 | IC50 | 0.16 | Preclinical |
| CHEMBL4784318 | 9.79 | Kd | 0.163 | Preclinical |